1-4 of 4
Andreas Viardot, MD PhD
Close
Sort by
Journal Articles

POLARGO: A Randomized Phase III Study Evaluating Polatuzumab Vedotin Plus Rituximab, Gemcitabine, and Oxaliplatin in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Who Had Received One or More Previous Therapies

Andrew K McMillan, FRCP, Matthew J Matasar, MD, Juan-Manuel Sancho, MD PhD, Andreas Viardot, MD PhD, Juana Hernandez, MD, Thomas Perretti, MD MSc, Corinne Haioun, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 5317.
https://doi.org/10.1182/blood-2019-123673
Published: 2019
Journal Articles

Rituximab and Bendamustine for First-Line Treatment of Frail or Elderly Patients with Aggressive B-Cell Lymphoma: Final Results of the Prospective Phase-II Brenda Trial of GLA (German Lymphoma Alliance)

Florian Zettl, Friederike Braulke, Marita Ziepert, PhD, Andreas Viardot, MD PhD, Christoph Kahl, MD, Gabriele Prange-Krex, Agnieszka Korfel, Martin H. Dreyling, MD PhD, Thomas Illmer, MD, Josef Birkmann, MD, Ulrich Wedding, Dietmar Reichert, Maike de Wit, MD, Frank Hartmann, MD, Hans-Juergen Hurtz, Norbert Schmitz, MD, Mathias Witzens-Harig, MD, Wolfram Klapper, Andreas Rosenwald, MD, Viola Poeschel, MD, Markus Loeffler, MD, Gerald Wulf, MD, Bettina Altmann, PhD, Lorenz Truemper, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4073.
https://doi.org/10.1182/blood-2019-122948
Published: 2019
Journal Articles

Conventional Immunochemotherapy (R-CHOEP) Vs High-Dose Immunochemotherapy (R-MegaCHOEP) in Younger Patients with High-Risk Aggressive B-Cell Lymphoma: 10-Year Long-Term Follow-up of a German Lymphoma Alliance (GLA) Study

Fabian Frontzek, MD, Marita Ziepert, PhD, Maike Nickelsen, Bettina Altmann, PhD, Bertram Glass, Mathias Hänel, MD, Lorenz Truemper, MD, Gerhard Held, MD, Martin Bentz, MD, Peter Borchmann, MD, Martin H. Dreyling, MD PhD, Andreas Viardot, MD PhD, Frank P. Kroschinsky, MDMBA, Bernd Metzner, MD PhD, Annette M. Staiger, PhD, Heike Horn, PhD, German Ott, MD, Andreas Rosenwald, MD, Markus Loeffler, MD, Georg Lenz, MD, Norbert Schmitz, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1589.
https://doi.org/10.1182/blood-2019-123637
Published: 2019
Journal Articles

Mature Response Data From a Phase 2 Study Of PI3K-Delta Inhibitor Idelalisib In Patients With Double (Rituximab and Alkylating Agent)-Refractory Indolent B-Cell Non-Hodgkin Lymphoma (iNHL)

Ajay Gopal, MD, Brad S. Kahl, MD, Sven De Vos, MD, PhD, Nina D. Wagner-Johnston, MD, Stephen J. Schuster, MD, Kristie A. Blum, MD, Wojciech J. Jurczak, Ian W. Flinn, MD, PhD, Christopher R. Flowers, MD, Peter Martin, MD, Andreas Viardot, MD, PhD, Andre Goy, MD, Andrew Davies, BM PhD, Pier Luigi Zinzani, MD, Martin H. Dreyling, MD, Leanne M. Holes, Daniel Li, PhD, Roger Dansey, MD, Wayne R. Godfrey, MD, Gilles A. Salles, MD, PhD
Journal: Blood
Blood (2013) 122 (21): 85.
https://doi.org/10.1182/blood.V122.21.85.85
Published: 2013